Aberrantly Glycosylated IgA1 as a Factor in the Pathogenesis of IgA Nephropathy

被引:16
作者
Tanaka, Mototsugu [1 ]
Seki, George [1 ]
Someya, Tomonosuke [2 ]
Nagata, Michio [3 ]
Fujita, Toshiro [1 ]
机构
[1] Univ Tokyo, Dept Internal Med, Fac Med, Bunkyo Ku, Tokyo 1130033, Japan
[2] Juntendo Univ, Sch Med, Dept Pediat, Tokyo 1138431, Japan
[3] Univ Tsukuba, Grad Sch Comprehens Human Sci, Tsukuba, Ibaraki 3058575, Japan
来源
CLINICAL & DEVELOPMENTAL IMMUNOLOGY | 2011年
关键词
HENOCH-SCHONLEIN PURPURA; GALACTOSE-DEFICIENT IGA1; TERM-FOLLOW-UP; GROWTH-FACTOR-BETA; LONG-TERM; IMMUNE-COMPLEXES; MYCOPHENOLATE-MOFETIL; O-GLYCOSYLATION; ACE-INHIBITORS; HINGE REGION;
D O I
10.1155/2011/470803
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Predominant or codominant immunoglobulin (Ig) A deposition in the glomerular mesangium characterizes IgA nephropathy (IgAN). Accumulated glomerular IgA is limited to the IgA1 subclass and usually galactose-deficient. This underglycosylated IgA may play an important role in the pathogenesis of IgAN. Recently, antibodies against galactose-deficient IgA1 were found to be well associated with the development of IgAN. Several therapeutic strategies based on corticosteroids or other immunosuppressive agents have been shown to at least partially suppress the progression of IgAN. On the other hand, several case reports of kidney transplantation or acquired IgA deficiency uncovered a remarkable ability of human kidney to remove mesangial IgA deposition, resulting in the long-term stabilization of kidney function. Continuous exposure to circulating immune complexes containing aberrantly glycosylated IgA1 and sequential immune response seems to be essential in the disease progression of IgAN. Removal of mesangial IgA deposition may be a challenging, but fundamental approach in the treatment of IgAN.
引用
收藏
页数:7
相关论文
共 62 条
  • [1] Mesangial IgA1 in IgA nephropathy exhibits aberrant O-glycosylation: Observations in three patients
    Allen, AC
    Bailey, EM
    Brenchley, PEC
    Buck, KS
    Barratt, J
    Feehally, J
    [J]. KIDNEY INTERNATIONAL, 2001, 60 (03) : 969 - 973
  • [2] Abnormal IgA glycosylation in Henoch-Schonlein purpura restricted to patients with clinical nephritis
    Allen, AC
    Willis, FR
    Beattie, TJ
    Feehally, J
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 1998, 13 (04) : 930 - 934
  • [3] [Anonymous], 1978, KIDNEY INT, V13, P159
  • [4] Berger J., 1968, J UROL NEPHROL, V74, P694
  • [5] DAMICO G, 1987, SEMIN NEPHROL, V7, P355
  • [6] DAMICO G, 1987, Q J MED, V64, P709
  • [7] IgA nephropathy
    Donadio, JV
    Grande, JP
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (10) : 738 - 748
  • [8] GLOMERULAR DISEASE ACEIs with or without corticosteroids in IgA nephropathy?
    Eitner, Frank
    Floege, Juergen
    [J]. NATURE REVIEWS NEPHROLOGY, 2010, 6 (05) : 252 - 254
  • [9] Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy:: a double-blind randomized controlled trial
    Frisch, G
    Lin, J
    Rosenstock, J
    Markowitz, G
    D'Agati, V
    Radhakrishnan, J
    Preddie, D
    Crew, J
    Valeri, A
    Appel, G
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2005, 20 (10) : 2139 - 2145
  • [10] IGA NEPHROPATHY
    GALLA, JH
    [J]. KIDNEY INTERNATIONAL, 1995, 47 (02) : 377 - 387